Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Multiple Myeloma - Pipeline industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Karyopharm Therapeutics, Inc
Oncopeptides AB
Ono Pharmaceutical Co, Ltd
Amgen, Inc
Nanjing Legend Pharmaceutical & Chemical Co, Ltd
bluebird bio
ImmunoGen, Inc
Bristol-Myers Squibb Company
Celgene Corporation
Takeda Pharmaceutical Company Ltd
F Hoffmann-La Roche AG (Genentech)
GlaxoSmithKline plc
Johnson & Johnson (Janssen)
AbbVie, Inc
Poseida Therapeutics, Inc
By Type:
B Cell Maturation Antigen (BCMA)-targeted Agents / CAR-T
Cell-Surface-targeted Agents (CD38 / SLAMF7)
Apoptosis-inducing Agents (BCL-2 Inhibitor)
Immunomodulatory Agents
Proteasome Inhibitors
Selective Inhibitors of Nuclear Export (SINE) / XPO1 Inhibitor
By Application:
Clinic
Hospital
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Multiple Myeloma - Pipeline Market Overview 2018-2029
-
1.1 China Multiple Myeloma - Pipeline Industry Development Overview
-
1.2 China Multiple Myeloma - Pipeline Industry Development History
-
1.3 China Multiple Myeloma - Pipeline Industry Market Size (2018-2029)
-
1.4 China Multiple Myeloma - Pipeline Market Analysis by Type from Production Side
-
1.4.1 China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of B Cell Maturation Antigen (BCMA)-targeted Agents / CAR-T (2018-2029)
-
1.4.2 China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Cell-Surface-targeted Agents (CD38 / SLAMF7) (2018-2029)
-
1.4.3 China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Apoptosis-inducing Agents (BCL-2 Inhibitor) (2018-2029)
-
1.4.4 China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Immunomodulatory Agents (2018-2029)
-
1.4.5 China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Proteasome Inhibitors (2018-2029)
-
1.4.6 China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Selective Inhibitors of Nuclear Export (SINE) / XPO1 Inhibitor (2018-2029)
-
1.5 China Multiple Myeloma - Pipeline Market Analysis by Application from Consumption End
-
1.5.1 China Multiple Myeloma - Pipeline Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)
-
1.5.2 China Multiple Myeloma - Pipeline Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)
-
1.6 China Multiple Myeloma - Pipeline Market Analysis by Region
-
1.6.1 North China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
Chapter 2 China Multiple Myeloma - Pipeline Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Multiple Myeloma - Pipeline Market Status and Competition at home and abroad in 2023
-
2.2.2 China Multiple Myeloma - Pipeline Market Status and Competition Analysis in 2023
-
2.2.3 China Multiple Myeloma - Pipeline Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Multiple Myeloma - Pipeline Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Multiple Myeloma - Pipeline Industry Development
Chapter 3 Multiple Myeloma - PipelineIndustry Chain Analysis
-
3.1 Multiple Myeloma - Pipeline Industry Chain
-
3.2 Multiple Myeloma - Pipeline Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Multiple Myeloma - Pipeline Market
-
3.3 Multiple Myeloma - Pipeline Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Multiple Myeloma - Pipeline Market
Chapter 4 China Multiple Myeloma - Pipeline Market, by Type
-
4.1 China Multiple Myeloma - Pipeline Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Multiple Myeloma - Pipeline Total Production Volume and Growth Rate from Production Side
-
4.5 China Multiple Myeloma - Pipeline Production Volume and Growth Rate, by Type
-
4.5.1 China Multiple Myeloma - Pipeline Production Volume and Growth Rate of B Cell Maturation Antigen (BCMA)-targeted Agents / CAR-T
-
4.5.2 China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Cell-Surface-targeted Agents (CD38 / SLAMF7)
-
4.5.3 China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Apoptosis-inducing Agents (BCL-2 Inhibitor)
-
4.5.4 China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Immunomodulatory Agents
-
4.5.5 China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Proteasome Inhibitors
-
4.5.6 China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Selective Inhibitors of Nuclear Export (SINE) / XPO1 Inhibitor
Chapter 5 China Multiple Myeloma - Pipeline Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Multiple Myeloma - Pipeline Total Market Size and Growth Rate from Consumption End
-
5.5 China Multiple Myeloma - Pipeline Market Size and Growth Rate, by Application
-
5.5.1 China Multiple Myeloma - Pipeline Market Size and Growth Rate of Clinic
-
5.5.2 China Multiple Myeloma - Pipeline Market Size and Growth Rate of Hospital
Chapter 6 China Multiple Myeloma - Pipeline Market, by Region
-
6.1 China Multiple Myeloma - Pipeline Production Volume and Production Value, by Region
-
6.2 China Multiple Myeloma - Pipeline Sales Volume and Sales Value, by Region
Chapter 7 North China Multiple Myeloma - Pipeline Market Analysis
-
7.1 North China Multiple Myeloma - Pipeline Market, by Type
-
7.2 North China Multiple Myeloma - Pipeline Market, by Application
Chapter 8 Central China Multiple Myeloma - Pipeline Market Analysis
-
8.1 Central China Multiple Myeloma - Pipeline Market, by Type
-
8.2 Central China Multiple Myeloma - Pipeline Market, by Application
Chapter 9 South China Multiple Myeloma - Pipeline Market Analysis
-
9.1 South China Multiple Myeloma - Pipeline Market, by Type
-
9.2 South China Multiple Myeloma - Pipeline Market, by Application
Chapter 10 East China Multiple Myeloma - Pipeline Market Analysis
-
10.1 East China Multiple Myeloma - Pipeline Market, by Type
-
10.2 East China Multiple Myeloma - Pipeline Market, by Application
Chapter 11 Northeast China Multiple Myeloma - Pipeline Market Analysis
-
11.1 Northeast China Multiple Myeloma - Pipeline Market, by Type
-
11.2 Northeast China Multiple Myeloma - Pipeline Market, by Application
Chapter 12 Southwest China Multiple Myeloma - Pipeline Market Analysis
-
12.1 Southwest China Multiple Myeloma - Pipeline Market, by Type
-
12.2 Southwest China Multiple Myeloma - Pipeline Market, by Application
Chapter 13 Northwest China Multiple Myeloma - Pipeline Market Analysis
-
13.1 Northwest China Multiple Myeloma - Pipeline Market, by Type
-
13.2 Northwest China Multiple Myeloma - Pipeline Market, by Application
Chapter 14 Company Profiles
-
14.1 Karyopharm Therapeutics, Inc
-
14.1.1 Karyopharm Therapeutics, Inc Company Profile
-
14.1.2 Karyopharm Therapeutics, Inc Multiple Myeloma - Pipeline Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Oncopeptides AB
-
14.2.1 Oncopeptides AB Company Profile
-
14.2.2 Oncopeptides AB Multiple Myeloma - Pipeline Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Ono Pharmaceutical Co, Ltd
-
14.3.1 Ono Pharmaceutical Co, Ltd Company Profile
-
14.3.2 Ono Pharmaceutical Co, Ltd Multiple Myeloma - Pipeline Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Amgen, Inc
-
14.4.1 Amgen, Inc Company Profile
-
14.4.2 Amgen, Inc Multiple Myeloma - Pipeline Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Nanjing Legend Pharmaceutical & Chemical Co, Ltd
-
14.5.1 Nanjing Legend Pharmaceutical & Chemical Co, Ltd Company Profile
-
14.5.2 Nanjing Legend Pharmaceutical & Chemical Co, Ltd Multiple Myeloma - Pipeline Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 bluebird bio
-
14.6.1 bluebird bio Company Profile
-
14.6.2 bluebird bio Multiple Myeloma - Pipeline Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 ImmunoGen, Inc
-
14.7.1 ImmunoGen, Inc Company Profile
-
14.7.2 ImmunoGen, Inc Multiple Myeloma - Pipeline Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Bristol-Myers Squibb Company
-
14.8.1 Bristol-Myers Squibb Company Company Profile
-
14.8.2 Bristol-Myers Squibb Company Multiple Myeloma - Pipeline Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Celgene Corporation
-
14.9.1 Celgene Corporation Company Profile
-
14.9.2 Celgene Corporation Multiple Myeloma - Pipeline Market Performance
-
14.9.3 Product&Service Introduction
-
14.10 Takeda Pharmaceutical Company Ltd
-
14.10.1 Takeda Pharmaceutical Company Ltd Company Profile
-
14.10.2 Takeda Pharmaceutical Company Ltd Multiple Myeloma - Pipeline Market Performance
-
14.10.3 Product&Service Introduction
-
14.11 F Hoffmann-La Roche AG (Genentech)
-
14.11.1 F Hoffmann-La Roche AG (Genentech) Company Profile
-
14.11.2 F Hoffmann-La Roche AG (Genentech) Multiple Myeloma - Pipeline Market Performance
-
14.11.3 Product&Service Introduction
-
14.12 GlaxoSmithKline plc
-
14.12.1 GlaxoSmithKline plc Company Profile
-
14.12.2 GlaxoSmithKline plc Multiple Myeloma - Pipeline Market Performance
-
14.12.3 Product&Service Introduction
-
14.13 Johnson & Johnson (Janssen)
-
14.13.1 Johnson & Johnson (Janssen) Company Profile
-
14.13.2 Johnson & Johnson (Janssen) Multiple Myeloma - Pipeline Market Performance
-
14.13.3 Product&Service Introduction
-
14.14 AbbVie, Inc
-
14.14.1 AbbVie, Inc Company Profile
-
14.14.2 AbbVie, Inc Multiple Myeloma - Pipeline Market Performance
-
14.14.3 Product&Service Introduction
-
14.15 Poseida Therapeutics, Inc
-
14.15.1 Poseida Therapeutics, Inc Company Profile
-
14.15.2 Poseida Therapeutics, Inc Multiple Myeloma - Pipeline Market Performance
-
14.15.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Multiple Myeloma - Pipeline Industry Research Conclusions
-
15.2 Multiple Myeloma - Pipeline Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Multiple Myeloma - Pipeline Industry Market Size (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of B Cell Maturation Antigen (BCMA)-targeted Agents / CAR-T (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Cell-Surface-targeted Agents (CD38 / SLAMF7) (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Apoptosis-inducing Agents (BCL-2 Inhibitor) (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Immunomodulatory Agents (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Proteasome Inhibitors (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Production Volume, Production Value and Growth Rate of Selective Inhibitors of Nuclear Export (SINE) / XPO1 Inhibitor (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)
-
Figure China Multiple Myeloma - Pipeline Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)
-
Figure North China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure Central China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure South China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure East China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Multiple Myeloma - Pipeline Market Size and Growth Rate from 2018-2029
-
Figure Multiple Myeloma - Pipeline Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Multiple Myeloma - Pipeline Market Share by Type in 2018
-
Figure China Multiple Myeloma - Pipeline Market Share by Type in 2023
-
Figure China Multiple Myeloma - Pipeline Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume and Growth Rate of B Cell Maturation Antigen (BCMA)-targeted Agents / CAR-T (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Cell-Surface-targeted Agents (CD38 / SLAMF7) (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Apoptosis-inducing Agents (BCL-2 Inhibitor) (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Immunomodulatory Agents (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Proteasome Inhibitors (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume and Growth Rate of Selective Inhibitors of Nuclear Export (SINE) / XPO1 Inhibitor (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Market Share by Application in 2018
-
Figure China Multiple Myeloma - Pipeline Market Share by Application in 2023
-
Figure China Multiple Myeloma - Pipeline Total Market Size and Growth Rate from Consumption End
-
Figure China Multiple Myeloma - Pipeline Market Size and Growth Rate of Clinic (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Market Size and Growth Rate of Hospital (2018-2023)
-
Table China Multiple Myeloma - Pipeline Production Volume by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Production Volume Share by Region (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Volume Share by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Production Value by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Production Value Share by Region (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Production Value Share by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Sales Volume by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Sales Volume Share by Region (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Sales Volume Share by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Sales Value by Region (2018-2023)
-
Table China Multiple Myeloma - Pipeline Sales Value Share by Region (2018-2023)
-
Figure China Multiple Myeloma - Pipeline Sales Value Share by Region (2018-2023)
-
Table North China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table North China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure North China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table North China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table North China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure North China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table Central China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table Central China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure Central China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table Central China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table Central China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure Central China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table South China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table South China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure South China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table South China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table South China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure South China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table East China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table East China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure East China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table East China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table East China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure East China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table Northeast China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table Northeast China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure Northeast China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table Northeast China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table Northeast China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table Southwest China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table Southwest China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure Southwest China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table Southwest China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table Southwest China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table Northwest China Multiple Myeloma - Pipeline Production Volume by Type (2018-2023)
-
Table Northwest China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Figure Northwest China Multiple Myeloma - Pipeline Production Volume Share by Type (2018-2023)
-
Table Northwest China Multiple Myeloma - Pipeline Sales Volume by Application (2018-2023)
-
Table Northwest China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Multiple Myeloma - Pipeline Sales Volume Share by Application (2018-2023)
-
Table Karyopharm Therapeutics, Inc Company Profile
-
Table Karyopharm Therapeutics, Inc Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Oncopeptides AB Company Profile
-
Table Oncopeptides AB Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Ono Pharmaceutical Co, Ltd Company Profile
-
Table Ono Pharmaceutical Co, Ltd Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Amgen, Inc Company Profile
-
Table Amgen, Inc Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Nanjing Legend Pharmaceutical & Chemical Co, Ltd Company Profile
-
Table Nanjing Legend Pharmaceutical & Chemical Co, Ltd Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table bluebird bio Company Profile
-
Table bluebird bio Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table ImmunoGen, Inc Company Profile
-
Table ImmunoGen, Inc Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Bristol-Myers Squibb Company Company Profile
-
Table Bristol-Myers Squibb Company Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Celgene Corporation Company Profile
-
Table Celgene Corporation Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Takeda Pharmaceutical Company Ltd Company Profile
-
Table Takeda Pharmaceutical Company Ltd Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table F Hoffmann-La Roche AG (Genentech) Company Profile
-
Table F Hoffmann-La Roche AG (Genentech) Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table GlaxoSmithKline plc Company Profile
-
Table GlaxoSmithKline plc Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Johnson & Johnson (Janssen) Company Profile
-
Table Johnson & Johnson (Janssen) Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table AbbVie, Inc Company Profile
-
Table AbbVie, Inc Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
Table Poseida Therapeutics, Inc Company Profile
-
Table Poseida Therapeutics, Inc Multiple Myeloma - Pipeline Revenue, Price and Gross (2018-2023)
-
